RxDoctor Payments Data

Daynet Hisley, MD

Neurology · Lakeland, FLNPI 1871814822

Payments from drug & device makers

$13,700in general payments, 2019–2025

Across 776 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$794
  • Amgen$627
  • Pfizer$620
  • Novartis$519
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$600%
  • Speaking & faculty fees$150%
  • Food & beverage$13,41498%
  • Education$2102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)155$2,127
Teva Pharmaceuticals USA, Inc.76$1,002
UCB, Inc.37$794
Amgen40$627
Pfizer40$620
Novartis36$519
Biohaven Pharmaceutical Holding Company Ltd.21$386
Avanir Pharmaceuticals, Inc.21$380
Lilly USA, LLC17$365
Biogen16$336
Argenx US, Inc.11$316
Bristol Myers Squibb13$315
SK Life Science, Inc.11$311
CSL Behring11$306
Eisai Inc.11$301
Lundbeck LLC11$271
Sunovion Pharmaceuticals Inc.18$270
GE HealthCare9$261
Supernus Pharmaceuticals, Inc.42$259
Neurocrine Biosciences, Inc.10$247
Otsuka America Pharmaceutical, Inc.10$230
AstraZeneca(2 entities)10$227
Genentech USA, Inc.9$205
Sanofi10$198
Neurelis, Inc.9$198
Catalyst Pharmaceuticals, Inc.8$194
Jazz Pharmaceuticals Inc.8$188
Acadia Pharmaceuticals Inc10$177
Tanabe Pharma America, Inc.6$168
Acorda Therapeutics, Inc7$159
EMD Serono, Inc.10$156
Vanda Pharmaceuticals Inc.4$111
TG Therapeutics, Inc.3$107
MDD US Operations, LLC5$107
Axsome Therapeutics, Inc.3$99
Novo Nordisk5$99
Livanova USA, Inc.3$77
Impel Pharmaceuticals Inc.4$75
Sumitomo Pharma America, Inc.3$64
Takeda Pharmaceuticals U.S.A., Inc.2$61
Sentynl Therapeutics, Inc.1$60
Penumbra, Inc.2$59
E.r. Squibb & Sons, L.L.C.3$58
Johnson & Johnson3$55
Boston Scientific2$47
Alnylam Pharmaceuticals Inc.3$46
Amneal Pharmaceuticals LLC3$45
Aucta Pharmaceuticals, Inc.4$45
Upsher-smith Laboratories LLC3$42
Aquestive Therapeutics, Inc.2$40
Collegium Pharmaceutical, Inc.2$39
Harmony Biosciences LLC2$37
Medtronic2$34
Adamas Pharmaceuticals, Inc.2$33
C2n Diagnostics, LLC1$29
Grifols USA, LLC1$26
Biohaven Pharmaceuticals, Inc.1$22
Greenwich Biosciences, Inc.1$22
Merz Pharmaceuticals, LLC1$19
Nevro Corp.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,700 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$330,429
Medicare patients
997
Services billed
18,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant131$197,589
Aimovig AutoinjectorErenumab-Aooe155$169,004
Kesimpta PenOfatumumab16$162,209
AustedoDeutetrabenazine21$138,187
Nurtec OdtRimegepant Sulfate87$120,611
CopaxoneGlatiramer Acetate16$94,771
Emgality PenGalcanezumab-Gnlm92$86,284
BotoxOnabotulinumtoxina56$72,637
NeuproRotigotine54$49,193
QuliptaAtogepant35$43,312
RexultiBrexpiprazole22$42,289
VimpatLacosamide34$37,602
BriviactBrivaracetam16$35,216
KeppraLevetiracetam17$31,786
AptiomEslicarbazepine Acetate24$29,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$2,127$313,538222 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,002$232,95737 claims
PfizerNurtec Odt, Lyrica, Dilantin$620$138,837129 claims
UCB, Inc.Neupro, Vimpat, Briviact$794$122,011104 claims
Otsuka America Pharmaceutical, Inc.Rexulti$230$42,28922 claims
Sunovion Pharmaceuticals Inc.Aptiom$270$29,18924 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$45$22,87187 claims
Eisai Inc.Fycompa$301$8,10611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →